Terazosin Capsule
Product Images NDC 71335-3059

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71335-3059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

Figure 1 from Study 1 shows two line graphs depicting the effects of Terazosin versus placebo over three months. The left graph shows mean change in total symptom score from baseline, with Terazosin reducing symptoms more than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with Terazosin showing greater improvement than placebo.*

FDA Label Image

Image Description (Figure 02)

A line graph titled 'Mean Change in Total Symptom Score from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis shows months from 0 to 30, and the y-axis shows mean change from baseline ranging from 0 to -7. The graph depicts a steady decrease in symptom score over time, leveling off after month 6, with data points marked by circles and several indicated by asterisks.*

FDA Label Image

Image Description (Figure 03)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months ranging from 0 to 30, and the y-axis shows the mean change from baseline in mL/sec peak flow rate, ranging from 0 to 4.5. Data points plotted with upward trend and some marked with asterisks indicating statistical significance.*

FDA Label Image

Label (Lbl713353059)

Label for Terazosin Capsules, USP 2 mg oral capsules, packaged as 30 capsules. The label includes NDC 71335-3059-1 and indicates the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by OrBion Pharmaceuticals Private Ltd. It advises storage between 20° to 25°C and protection from light and moisture.*

FDA Label Image

Image Description (Structure001)

Chemical structure of Terazosin hydrochloride dihydrate, showing its molecular framework including aromatic rings, piperazine and oxazolidinone groups, and associated hydrochloride and water molecules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.